Production (Stage)
Context Therapeutics Inc.
CNTX
$0.6114
-$0.018-2.86%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.14% | -0.92% | -4.52% | -10.30% | -10.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.29% | 19.35% | 47.79% | 0.69% | 22.78% |
| Operating Income | -42.29% | -19.35% | -47.79% | -0.69% | -22.78% |
| Income Before Tax | -29.60% | -11.52% | -45.30% | 0.87% | -20.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.60% | -11.52% | -45.30% | 0.87% | -20.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.60% | -11.52% | -45.30% | 0.87% | -20.43% |
| EBIT | -42.29% | -19.35% | -47.79% | -0.69% | -22.78% |
| EBITDA | -42.30% | -19.36% | -47.83% | -0.70% | -22.79% |
| EPS Basic | 74.03% | 64.79% | 29.86% | 9.43% | -20.42% |
| Normalized Basic EPS | 74.03% | 64.79% | 29.85% | 9.41% | -23.95% |
| EPS Diluted | 70.84% | 61.96% | 29.86% | 9.43% | -20.42% |
| Normalized Diluted EPS | 74.03% | 64.79% | 29.85% | 9.41% | -23.95% |
| Average Basic Shares Outstanding | 389.41% | 265.36% | 162.07% | 61.06% | 0.00% |
| Average Diluted Shares Outstanding | 389.41% | 265.36% | 162.07% | 61.06% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |